This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

VEN 308

Assembly Biosciences, Inc.

Drug Names(s): VEN 308, phenylephrine gel

Description: Phenylephrine gel increases anal sphincter tone, thereby improving fecal incontinence in patients where sphincter tone is the major cause of their symptoms (such as post IPAA surgery). Topical phenylephrine improves patient bowel control.

Deal Structure: Ventrus licensed the exclusive North American rights for VEN 308 as a topical treatment for fecal incontinence from S.L.A Pharma, who expects to conduct a European development program.

Assembly and Ventrus
In May 2014, Ventrus Biosciences entered into a merger agreement with Assembly Pharmaceuticals in an all-stock transaction. Upon the completion of the merger, the combined company will be renamed Assembly Biosciences, Inc. and trade on the Nasdaq Capital Market under the ticker ASMB.

Once the merger is complete, the company will focus on the development of Assembly's novel, first-in-class small molecules to treat, and potentially cure, hepatitis B virus (HBV) infection. Pursuant to the Merger Agreement, Ventrus will issue approximately 23 million shares of common stock to the Assembly stockholders. At the time of issuance, 20,322,760 of the shares will be issued common stock and 2,829,740 shares will be shares underlying stock options of...See full deal structure in Biomedtracker

VEN 308 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug